Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: Growth inhibition, quiescence, and recovery

Journal of Cellular Physiology

Volumn 228, Issue 2, 2013, Pages 292-297

  Carr, Brian I ^a   Cavallini, Aldo ^a   Lippolis, Catia ^a   D'Alessandro, Rosalba ^a   Messa, Caterina ^a   Refolo, Maria G ^a   Tafaro, Angela ^a  

^a NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BECLIN 1; CASPASE; DOXORUBICIN; PROTEIN BAX; REGORAFENIB;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CELL GROWTH; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; GROWTH INHIBITION; HEPATOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; HUMANS; LIVER NEOPLASMS; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PYRIDINES; SIGNAL TRANSDUCTION;

EID: 84868035144     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24148     Document Type: Article

References (23)

1. Adnane L, Trail PA, Taylor I, Wilhelm SM. 2006. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 407:597-612.
2. Barkan D, Green JE, Chambers AF. 2010. Extracellular matrix: A gatekeeper in the transition from dormancy to metastatic growth. Eur J Cancer 46:1181-1188.
3. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. 2009. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25-34.
4. Codogno P, Mehrpour M, Proikas-Cezanne T. 2011. Canonical and non-canonical autophagy: Variations on a common theme of self-eating? Nat Rev Mol Cell Biol 13:7-12.
5. Dumas J, Sibley R, Riedl B, Monahan MK, Lee W, Lowinger TB, Redman AM, Johnson JS, Kingery-Wood J, Scott WJ, Smith RA, Bobko M, Schoenleber R, Ranges GE, Housley TJ, Bhargava A, Wilhelm SM, Shrikhande A. 2000. Discovery of a new class of p38 kinase inhibitors. Bioorg Med Chem Lett 10:2047-2050.
6. Gish RG, Porta C, Lazar L, Ruff P, Feld R, Croitoru A, Feun L, Jeziorski K, Leighton J, Gallo J, Kennealey GT. 2007. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol 25:3069-3075.
7. Goss PE, Chambers AF. 2010. Does tumour dormancy offer a therapeutic target? Nat Rev Cancer 10:871-877.
8. Guo XZ, Shao XD, Liu MP, Xu JH, Ren LN, Zhao JJ, Li HY, Wang D. 2002. Effect of bax, bcl-2 and bcl-xL on regulating apoptosis in tissues of normal liver and hepatocellular carcinoma. World J Gastroenterol 8:1059-1062.
9. Guo L, Dial S, Shi L, Branham W, Liu J, Fang JL, Green B, Deng H, Kaput J, Ning B. 2011. Similarities and differences in the expression of drug-metabolizing enzymes between human hepatic cell lines and primary human hepatocytes. Drug Metab Dispos 39:528-533.
10. Huynh H. 2010. Molecularly targeted therapy in hepatocellular carcinoma. Biochem Pharmacol 80:550-560.
11. Kimmelman AC. 2010. The dynamic nature of autophagy in cancer. Genes Dev 25:1999-2010.
12. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C. 2006. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66:11851-11858.
13. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, SHARP Investigators Study Group. 2008. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390.
14. Matsuda Y, Fukumoto M. 2011. Sorafenib: Complexities of Raf-dependent and Raf-independent signaling are now unveiled. Med Mol Morphol 44:183-189.
15. McClendon AK, Dean JL, Ertel A, Fu Z, Rivadeneira DB, Reed CA, Bourgo RJ, Witkiewicz A, Addya S, Mayhew CN, Grimes HL, Fortina P, Knudsen ES, 2011. RB and p53 cooperate to 1439 prevent liver tumorigenesis in response to tissue damage. Gastroenterology 141:1439-1450.
16. Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N, Packer M, Schneider MD, Levine B. 2005. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 122:927-939.
17. Sosa MS, Avivar-Valderas A, Bragado P, Wen HC, Aguirre-Ghiso JA. 2011. ERK1/2 and p38α/β signaling in tumor cell quiescence: Opportunities to control dormant residual disease. Clin Cancer Res 17:5850-5857.
18. Wei G, Wang M, Hyslop T, Wang Z, Carr BI. 2010. Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo. Int J Cancer 127:2949-2958.
19. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA. 2004. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109.
20. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. 2008. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7:3129-3140.
21. Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schütz G, Thierauch KH, Zopf D. 2011. Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129:245-255.
22. Wörns MA, Galle PR. 2010. Novel inhibitors in development for hepatocellular carcinoma. Expert Opin Investig Drugs 19:615-629.
23. Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY, Koh J, Mo FK, Yu SC, Chan AT, Hui P, Ma B, Lam KC, Ho WM, Wong HT, Tang A, Johnson PJ. 2005. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 97:1532-1538.